Saphris Articles
Two UK product launches
16 January 2012
Regulatory briefs: Allergic reactions warning on Merck & Co’s Saphris; Eisai drops Pariet ER development
2 September 2011
Denmark’s Lundbeck buys rights to Merck & Co’s antipsychotic Sycrest; enters deal with Genmab
13 October 2010
Merck & Co’s integrated pipeline has over 20 drugs and vaccines in late-stage development
2 March 2010
Emerging oral atypical antipsychotics will garner only limited uptake in schizophrenia market
25 February 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
Schering-Plough gets US approval for Saphris
17 August 2009
FDA Committee backs Schering-Plough’s Saphris
3 August 2009
S-P responds to FDA's questions on Saphris NDA
2 March 2009
FDA requests more existing data on S-P's Saphris before approval
19 January 2009
S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years
8 December 2008
S-P's Saphris effective in schizophrenia relapse
1 December 2008
Showing 1-16 of 16 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
